Accepted for Publication: June 27, 2021.
Published Online: August 25, 2021. doi:10.1001/jamapsychiatry.2021.2332
Correction: This article was corrected on October 6, 2021, to fix a sentence in the second paragraph of the Discussion that had erroneously begun with “Third” instead of “Fourth.”
Corresponding Author: Brandon Nichter, PhD, Department of Psychiatry, University of California, San Diego, 9500 Gilman Dr, La Jolla, CA 92093 (email@example.com).
Author Contributions: Dr Pietrzak had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Nichter, Hill, Kline, Norman, Southwick, Pietrzak.
Acquisition, analysis, or interpretation of data: Nichter, Hill, Na, Krystal, Pietrzak.
Drafting of the manuscript: Nichter, Pietrzak.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Nichter, Pietrzak.
Obtained funding: Krystal, Pietrzak.
Administrative, technical, or material support: Krystal, Pietrzak.
Supervision: Southwick, Pietrzak.
Conflict of Interest Disclosures: Dr Southwick reported receiving financial support from the Glenn H. Greenberg Endowed Professorship of Psychiatry, PTSD, and Resilience, Yale University School of Medicine. Dr Krystal reported being a scientific adviser to Biohaven Pharmaceuticals, BioXcel Therapeutics, Inc, Cadent Therapeutics (Clinical Advisory Board), PsychoGenics, Inc, Stanley Center for Psychiatric Research at the Broad Institute of MIT and Harvard, and Lohocla Research Corporation. Dr Krystal reported owning stock and/or stock options in Biohaven Pharmaceuticals, Sage Pharmaceuticals, Spring Care, Inc, BlackThorn Therapeutics, Inc, and Terran Biosciences, Inc. Dr Krystal reported receiving less than $10 000 in income (consulting fees) per year from AstraZeneca Pharmaceuticals, Biogen, Idec, MA, Biomedisyn Corporation, Bionomics, Limited (Australia), Boehringer Ingelheim International, Concert Pharmaceuticals, Inc, Epiodyne, Inc, Heptares Therapeutics, Limited (UK), Janssen Research & Development, L.E.K. Consulting, Otsuka America Pharmaceutical, Inc, Perception Neuroscience Holdings, Inc, Spring Care, Inc, Sunovion Pharmaceuticals, Inc, Takeda Industries, and Taisho Pharmaceutical Co, Ltd. Dr Krystal reported receiving income of greater than $10 000 per year from Biological Psychiatry as an editor. Dr Krystal reported receiving the drug Saracatinib for use in research studies from AstraZeneca and Mavoglurant from Novartis for research related to the National Institute on Alcohol Abuse and Alcoholism grant “Center for Translational Neuroscience of Alcoholism from AstraZeneca Pharmaceuticals.” Dr Krystal reported having the following patents: (1) Seibyl JP, Krystal JH, Charney DS. Dopamine and noradrenergic reuptake inhibitors in treatment of schizophrenia. US Patent 5447948; September 5, 1995; (2) Coric V, Krystal JH, Sanacora G. Glutamate Modulating Agents in the Treatment of Mental Disorders. US Patent 8778979 B2. July 15, 2014. US Patent Application No. 15/695164; filing date, September 5, 2017; (3) Charney D, Krystal JH, Manji H, Matthew S, Zarate C. Intranasal Administration of Ketamine to Treat Depression. US application 14/197767 filed on March 5, 2014; US Application or Patent Cooperation Treaty International Application 14/306382 filed on June 17, 2014; (4) Zarate C, Charney DS, Manji HK, Mathew SJ, Krystal JH, Department of Veterans Affairs. Methods for Treating Suicidal Ideation, Patent Application 14/197.767 filed on March 5, 2014, by Yale University Office of Cooperative Research; (5) Arias A, Petrakis I, Krystal JH. Composition and methods to treat addiction. Provisional Use Patent Application 61/973/961 filed on April 2, 2014, by Yale University Office of Cooperative Research; (6) Chekroud A, Gueorguieva R, Krystal JH. Treatment Selection for Major Depressive Disorder, filed on June 3, 2016, USPTO docket Y0087.70116US00. Provisional patent submission by Yale University; (7) Gihyun Y, Petrakis I, Krystal JH. Compounds, Compositions and Methods for Treating or Preventing Depression and Other Diseases. US Provisional Patent Application 62/444552, filed on January 10, 2017, by Yale University Office of Cooperative Research OCR 7088 US01; and (8) Abdallah C, Krystal JH, Duman R, Sanacora G. Combination Therapy for Treating or Preventing Depression or Other Mood Diseases. US Provisional Patent Application 62/719935 filed on August 20, 2018, by Yale University Office of Cooperative Research OCR 7451 US01. Dr Krystal reported receiving provision of drug from Cerevel and Novartis; stock options from Biohaven Pharmaceuticals, RBNC, Sage, Epivario, Terran, Atai, and Spring Care; patent royalties from Janssen Pharmaceuticals; and personal fees from Biogen, Neurocrine, Takeda, Jazz, Aptinyx, Bionomics, Compass, Concert, Epiodyne, Sunovion, Taisho, BioXcel, Eisai, Psychogenics, Greenwich Biosciences, and Boehringer Ingelheim for advising on clinical trials. In addition, Dr Krystal reported having patent No. 8,778,979 with royalties paid from Biohaven for Use of Glutamate Modulating Agents in the Treatment of Mental Disorders, patent 9,592,207 with royalties paid from Janssen Intranasal for Administration of Ketamine to Treat Depression, and patent 15,379,013 with royalties paid from Janssen Methods for Treating Suicidal Ideation outside the submitted work. Dr Norman reported receiving grants from the Department of Defense, the US Department of Veterans Affairs, and Patient-Centered Outcomes Research Institute and personal fees from Elsevier Press and UptoDate outside the submitted work. No other disclosures were reported.
Funding/Support: The National Health and Resilience in Veterans Study was supported by the US Department of Veterans Affairs National Center for Posttraumatic Stress Disorder.
Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Additional Contributions: We thank the veterans who participated in this study.
World Health Organization. Policy Brief: COVID-19 and the Need for Action on Mental Health. World Health Organization; 2020.
MÉ , Lane
RI , Wiley
JF , Czeisler
CA , Howard
ME , Rajaratnam
SMW . Follow-up survey of US adult reports of mental health, substance use, and suicidal ideation during the COVID-19 pandemic, September 2020. JAMA Netw Open
. 2021;4(2):e2037665. doi:10.1001/jamanetworkopen.2020.37665
B , Norman
S , Haller
M , Pietrzak
RH . Psychological burden of PTSD, depression, and their comorbidity in the U.S. veteran population: suicidality, functioning, and service utilization. J Affect Disord
. 2019;256:633-640. doi:10.1016/j.jad.2019.06.072
United States Department of Veterans Affairs. 2019 National Veteran Suicide Prevention Annual Report. US Department of Health and Human Services; 2020.
CJ , Bryan
AO , Baker
JC . Associations among state-level physical distancing measures and suicidal thoughts and behaviors among US adults during the early COVID-19 pandemic. Suicide Life Threat Behav
. 2020;50(6):1223-1229. doi:10.1111/sltb.12653
J , Schick
V , Hernandez
B , Pietrzak
RH . Is homelessness a traumatic event? results from the 2019-2020 National Health and Resilience in Veterans Study. Depress Anxiety
. 2020;37(11):1137-1145. doi:10.1002/da.23098
CA , Weathers
FW , Davis
MT , Witte
TK , Domino
JL . The posttraumatic stress disorder checklist for DSM-5 (PCL-5): development and initial psychometric evaluation. J Trauma Stress
. 2015;28(6):489-498. doi:10.1002/jts.22059
F , Blake
D , Schnurr
P , Kaloupek
D , Marx
B , Keane
T . Life Events Checklist for DSM-5 (LEC-5). National Center for PTSD; 2018.
JB , Aasland
OG , Babor
TF , de la Fuente
JR , Grant
M . Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption—II. Addiction
. 1993;88(6):791-804. doi:10.1111/j.1360-0443.1993.tb02093.x
L , Sharp
C , Stanford
MS , Tharp
AT . New tricks for an old measure: the development of the Barratt Impulsiveness Scale-Brief (BIS-Brief). Psychol Assess
. 2013;25(1):216-226. doi:10.1037/a0030550
B , Compton
WM , Gfroerer
J , McKeon
R . Prevalence and correlates of past 12-month suicide attempt among adults with past-year suicidal ideation in the United States. J Clin Psychiatry
. 2015;76(3):295-302. doi:10.4088/JCP.14m09287
RH , Tsai
J , Southwick
SM . Association of symptoms of posttraumatic stress disorder with posttraumatic psychological growth among US veterans during the COVID-19 pandemic. JAMA Netw Open
. 2021;4(4):e214972. doi:10.1001/jamanetworkopen.2021.4972
TE , Hollar
D , Van Orden
K . On Buckeyes, Gators, Super Bowl Sunday, and the Miracle on Ice: “pulling together” is associated with lower suicide rates. J Soc Clin Psychol
. 2006;25(2):179-195. doi:10.1521/jscp.2006.25.2.179
TE , Van Orden
KA , Witte
TK , Rudd
MD . The Interpersonal Theory of Suicide: Guidance for Working with Suicidal Clients.
American Psychological Association; 2009. doi:10.1037/11869-000
RH , Goldstein
MB , Malley
JC , Rivers
AJ , Johnson
DC , Southwick
SM . Risk and protective factors associated with suicidal ideation in veterans of Operations Enduring Freedom and Iraqi Freedom. J Affect Disord
. 2010;123(1-3):102-107. doi:10.1016/j.jad.2009.08.001
B , Stein
MB , Norman
et al. Prevalence, correlates, and treatment of suicidal behavior in US Military veterans: results from the 2019–2020 National Health and Resilience in Veterans Study. J Clin Psychiatry
. 2021;82(00):20m13714.Google Scholar
B , Hill
M , Norman
S , Haller
M , Pietrzak
RH . Associations of childhood abuse and combat exposure with suicidal ideation and suicide attempt in US military veterans: a nationally representative study. J Affect Disord
. 2020;276:1102-1108. doi:10.1016/j.jad.2020.07.120
B , Norman
SB , Maguen
S , Pietrzak
RH . Moral injury and suicidal behavior among US combat veterans: results from the 2019-2020 National Health and Resilience in Veterans Study. Depress Anxiety
. 2021;38(6):606-614. doi:10.1002/da.23145PubMedGoogle ScholarCrossref
van de Mortal
TF, . Faking it: social desirability response bias in self-report research. Aust J Adv Nurs
. 2008;25(4):40-48.Google Scholar
B , Hill
M , Norman
S , Haller
M , Pietrzak
RH . Mental health treatment utilization among US military veterans with suicidal ideation: results from the National Health and Resilience in Veterans Study. J Psychiatr Res
. 2020;130:61-67. doi:10.1016/j.jpsychires.2020.07.004PubMedGoogle ScholarCrossref